Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals

Author(s):  
Christoffer Martinussen ◽  
Maria S Svane ◽  
Kirstine N Bojsen-Møller ◽  
Christian Zinck Jensen ◽  
Viggo B Kristiansen ◽  
...  

Growth differentiating factor 15 (GDF15) is expressed in the intestine and is one of the most recently identified satiety peptides. The mechanisms controlling its secretion are unclear. The present study investigated whether plasma GDF15 concentrations are meal-related and if potential responses depend on macronutrient type or are affected by previous bariatric surgery. The study included: (1) volunteers ingesting rapidly vs. slowly digested carbohydrates (sucrose vs. isomaltose) (n=10), (2) volunteers who had undergone Roux-en-Y Gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery and unoperated matched controls ingesting a liquid mixed meal (n=9-10 in each group), and (3) individuals with previous RYGB compared with unoperated controls ingesting isocaloric glucose, fat or protein (n=6 in each group). Plasma was collected after an overnight fast and up to 6 h after ingestion (≥12 timepoints). In cohort 1, fasting GDF15 concentrations were ~480 pg/ml. Concentrations after sucrose or isomaltose intake did not differ from baseline (P=0.26-P>0.99) and total area-under-the-curves (tAUCs were similar between groups (P=0.77). In cohort 2, fasting GDF15 concentrations were (pg/ml): RYGB=540±41.4, SG=477±36.4, and controls=590±41.8, with no between-group differences (P=0.73). Concentrations did not increase at any postprandial time point (over all time factor: P=0.10) and tAUCs were similar between groups (P=0.73). In cohort 3, fasting plasma GDF15 was similar among the groups (P>0.99) and neither glucose, fat or protein intake consistently increased the concentrations. In conclusion, we find that plasma GDF15 was not stimulated by meal intake, and that fasting concentrations did not differ between RYGB, SG and BMI-matched controls when investigated during the weight stable phase after RYGB and SG.

2015 ◽  
Vol 26 (7) ◽  
pp. 1448-1456 ◽  
Author(s):  
Eivind Grong ◽  
Hallvard Græslie ◽  
Bjørn Munkvold ◽  
Ingerid Brænne Arbo ◽  
Bård Erik Kulseng ◽  
...  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2315-PUB
Author(s):  
JENNY TONG ◽  
RAFAEL ALVAREZ ◽  
GREGORY B. RUSSELL ◽  
ALEXANDER N. KHOURI ◽  
RANDY J. SEELEY ◽  
...  

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 878
Author(s):  
Arnaud Bernard ◽  
Johanne Le Beyec-Le Bihan ◽  
Loredana Radoi ◽  
Muriel Coupaye ◽  
Ouidad Sami ◽  
...  

The aim of this study was to explore the impact of bariatric surgery on fat and sweet taste perceptions and to determine the possible correlations with gut appetite-regulating peptides and subjective food sensations. Women suffering from severe obesity (BMI > 35 kg/m2) were studied 2 weeks before and 6 months after a vertical sleeve gastrectomy (VSG, n = 32) or a Roux-en-Y gastric bypass (RYGB, n = 12). Linoleic acid (LA) and sucrose perception thresholds were determined using the three-alternative forced-choice procedure, gut hormones were assayed before and after a test meal and subjective changes in oral food sensations were self-reported using a standardized questionnaire. Despite a global positive effect of both surgeries on the reported gustatory sensations, a change in the taste sensitivity was only found after RYGB for LA. However, the fat and sweet taste perceptions were not homogenous between patients who underwent the same surgery procedure, suggesting the existence of two subgroups: patients with and without taste improvement. These gustatory changes were not correlated to the surgery-mediated modifications of the main gut appetite-regulating hormones. Collectively these data highlight the complexity of relationships between bariatric surgery and taste sensitivity and suggest that VSG and RYGB might impact the fatty taste perception differently.


2020 ◽  
Author(s):  
Cristina Fiorani ◽  
Sophie R. Coles ◽  
Myutan Kulendran ◽  
Emma Rose McGlone ◽  
Marcus Reddy ◽  
...  

Abstract Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) have been shown to improve metabolic comorbidities as well as quality of life (QoL) in the obese population. The vast majority of previous studies have investigated the metabolic effects of bariatric surgery and there is a dearth of studies examining long-term QoL outcomes post bariatric surgery. The outcomes of 43 patients who underwent bariatric surgery were prospectively assessed, using BAROS questionnaires to quantify QoL and metabolic status pre-operatively, at 1 year and at 8 years. Total weight loss and comorbidity resolution were similar between RYGB and SG. The RYGB cohort experienced greater QoL improvement from baseline and had higher BAROS scores at 8 years. RYGB may provide more substantial and durable long-term benefits as compared to SG.


Sign in / Sign up

Export Citation Format

Share Document